Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Pediatrics Reports
Published in: Current Pediatrics Reports 1/2015

01-03-2015 | Immunology (HB Gaspar, Section Editor)

Hematopoietic Stem Cell Transplantation for Severe Combined Immunodeficiency

Authors: Justin T. Wahlstrom, Christopher C. Dvorak, Morton J. Cowan

Published in: Current Pediatrics Reports | Issue 1/2015

Login to get access

Abstract

Hematopoietic stem cell transplantation is an effective approach for the treatment of severe combined immunodeficiency (SCID). However, SCID is not a homogeneous disease, and the treatment required for successful transplantation varies significantly between SCID subtypes and the degree of HLA mismatch between the best available donor and the patient. Recent studies are beginning to more clearly define this heterogeneity and how outcomes may vary. With a more detailed understanding of SCID, new approaches can be developed to maximize immune reconstitution, while minimizing acute and long-term toxicities associated with chemotherapy conditioning.
Literature
1.
Geha RS, et al. Primary immunodeficiency diseases: an update from the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee. J Allergy Clin Immunol. 2007;120:776–94.CrossRefPubMedCentralPubMed
2.
• Shearer WT et al. Establishing diagnostic criteria for severe combined immunodeficiency disease (SCID), leaky SCID, and Omenn syndrome: the primary immune deficiency treatment consortium experience. J Allergy Clin Immunol. 2014;133:1092–8. Provides the rationale and detailed analysis of criteria for making a diagnosis of SCID.
3.
Kwan A, et al. Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States. JAMA. 2014;312:729–38.CrossRefPubMed
4.
5.
6.
Buckley RH, et al. Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. N Engl J Med. 1999;340:508–16.CrossRefPubMed
7.
Railey MD, Lokhnygina Y, Buckley RH. Long-term clinical outcome of patients with severe combined immunodeficiency who received related donor bone marrow transplants without pretransplant chemotherapy or post-transplant GVHD prophylaxis. J Pediatr. 2009;155:834–40.CrossRefPubMedCentralPubMed
8.
•• Pai SY et al. Transplantation outcomes for severe combined immunodeficiency, 2000–2009. N Engl J Med 2014;371:434–46. This is the most recent retrospective study of a multi-institutional (PIDTC) cohort of over 200 SCID patients. The impact of SCID type, infection status, age at transplant, donor type, and conditioning regimen on immune reconstitution, GVHD, and survival are reported in detail. It showed that transplantation prior to infection is essential to maximize likelihood of survival.
9.
Kwan A, et al. Newborn screening for severe combined immunodeficiency and T-cell lymphopenia in California: results of the first 2 years. J Allergy Clin Immunol. 2013;132:140–50.CrossRefPubMedCentralPubMed
10.
Puck JM. Laboratory technology for population-based screening for severe combined immunodeficiency in neonates: the winner is T-cell receptor excision circles. J Allergy Clin Immunol. 2012;129:607–16.CrossRefPubMedCentralPubMed
11.
• Dvorak CC et al. The natural history of children with severe combined immunodeficiency: baseline features of the first fifty patients of the primary immune deficiency treatment consortium prospective study 6901. J Clin Immunol. 2013;33:1156–64. This report of the first 50 patients enrolled on the prospective multi-institutional (PIDTC) SCID study details the characteristics of SCID patients in the era of routine newborn screening and how this has affected the timing of HSCT.
12.
• Dvorak CC et al. Comparison of outcomes of hematopoietic stem cell transplantation without chemotherapy conditioning by using matched sibling and unrelated donors for treatment of severe combined immunodeficiency. J Allergy Clin Immunol 2014;134:935–43. This study of over 100 unconditioned SCID transplants reported the effects of SCID type, donor type, and serotherapy on outcomes including immune reconstitution, GVHD, and survival. It showed that unconditioned transplants using unrelated donors result in acceptable rates of GVHD and survival.
13.
Dvorak CC, et al. Megadose CD34(+) cell grafts improve recovery of T cell engraftment but not B cell immunity in patients with severe combined immunodeficiency disease undergoing haplocompatible nonmyeloablative transplantation. Biol Blood Marrow Transplant. 2008;14:1125–33.CrossRefPubMed
14.
• Buckley RH et al. Post-transplantation B cell function in different molecular types of SCID. J Clinical Immunol. 2013;33:96–110. This study provides a deeper analysis of how SCID type affects post-transplant immune reconstitution.
15.
Recher M, et al. IL-21 is the primary common gamma chain-binding cytokine required for human B-cell differentiation in vivo. Blood. 2011;118:6824–35.CrossRefPubMedCentralPubMed
16.
Mazzolari E, et al. Long-term immune reconstitution and clinical outcome after stem cell transplantation for severe T-cell immunodeficiency. J Allergy Clin Immunol. 2007;120:892–9.CrossRefPubMed
17.
Grunebaum E, et al. Bone marrow transplantation for severe combined immune deficiency. JAMA. 2006;295:508–18.CrossRefPubMed
18.
• Haddad E, Leroy S, Buckley RH. B-cell reconstitution for SCID: should a conditioning regimen be used in SCID treatment? J Allergy Clin Immunol. 2013;131:994–1000. This review discusses the advantages and disadvantages of using conditioning in patients with SCID.
19.
Cavazzana-Calvo M, et al. Long-term T-cell reconstitution after hematopoietic stem-cell transplantation in primary T-cell-immunodeficient patients is associated with myeloid chimerism and possibly the primary disease phenotype. Blood. 2007;109:4575–81.CrossRefPubMed
20.
Sarzotti M, et al. T cell repertoire development in humans with SCID after nonablative allogeneic marrow transplantation. J Immunol. 2003;170:2711–8.CrossRefPubMed
21.
Rao K, et al. Improved survival after unrelated donor bone marrow transplantation in children with primary immunodeficiency using a reduced-intensity conditioning regimen. Blood. 2005;105:879–85.CrossRefPubMed
22.
Slatter MA, et al. Treosulfan-based conditioning regimens for hematopoietic stem cell transplantation in children with primary immunodeficiency: United Kingdom experience. Blood. 2011;117:4367.CrossRefPubMed
23.
Robertson LE, et al. Natural killer cell activity in chronic lymphocytic leukemia patients treated with fludarabine. Cancer Chemother Pharmacol. 1996;37:445–50.CrossRefPubMed
24.
Dvorak CC, et al. A trial of alemtuzumab adjunctive therapy in allogeneic hematopoietic cell transplantation with minimal conditioning for severe combined immunodeficiency. Pediatr Transplant. 2014;18:609.CrossRefPubMed
25.
Myers LA, Patel DD, Puck JM, Buckley RH. Hematopoietic stem cell transplantation for severe combined immunodeficiency in the neonatal period leads to superior thymic output and improved survival. Blood. 2002;99:872–8.CrossRefPubMed
26.
27.
28.
Fernandes JF, et al. Transplantation in patients with SCID: mismatched related stem cells or unrelated cord blood? Blood. 2012;119:2949–55.CrossRefPubMed
29.
Gluckman E, et al. Milestones in umbilical cord blood transplantation. Br J Haematol. 2011;154:441–7.CrossRefPubMed
30.
Gennery AR, et al. Transplantation of hematopoietic stem cells and long-term survival for primary immunodeficiencies in Europe: entering a new century, do we do better? J Allergy Clin Immunol. 2010;126:602–10.CrossRefPubMed
31.
Muller SM, et al. Transplacentally acquired maternal T lymphocytes in severe combined immunodeficiency: a study of 121 patients. Blood. 2001;98:1847–51.CrossRefPubMed
32.
Palmer BE, Mack DG, Martin AK, Maier LA, Fontenot AP. CD57 expression correlates with alveolitis severity in subjects with beryllium-induced disease. J Allergy Clin Immunol. 2007;120:184–91.CrossRefPubMed
33.
Scaradavou A, Carrier C, Mollen N, Stevens C, Rubinstein P. Detection of maternal DNA in placental/umbilical cord blood by locus-specific amplification of the noninherited maternal HLA gene. Blood. 1996;88:1494–500.PubMed
34.
Knobloch C, Goldmann SF, Friedrich W. Limited T cell receptor diversity of transplacentally acquired maternal T cells in severe combined immunodeficiency. J Immunol. 1991;146:4157–64.PubMed
35.
Palmer K, et al. Unusual clinical and immunologic manifestations of transplacentally acquired maternal T cells in severe combined immunodeficiency. J Allergy Clin Immunol. 2007;120:423–8.CrossRefPubMed
36.
37.
Dror Y, et al. Immune reconstitution in severe combined immunodeficiency disease after lectin-treated, T-cell-depleted haplocompatible bone marrow transplantation. Blood. 1993;81:2021–30.PubMed
38.
Haddad E, et al. Long-term immune reconstitution and outcome after HLA-nonidentical T-cell-depleted bone marrow transplantation for severe combined immunodeficiency: a European retrospective study of 116 patients. Blood. 1998;91:3646–53.PubMed
39.
Long-Boyle JR, et al. High fludarabine exposure and relationship with treatment-related mortality after nonmyeloablative hematopoietic cell transplantation. Bone Marrow Transplant. 2011;46:20–6.CrossRefPubMedCentralPubMed
40.
Antoine C, et al. Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968–99. Lancet. 2003;361:553–60.CrossRefPubMed
41.
Neven B, et al. Long-term outcome after hematopoietic stem cell transplantation of a single-center cohort of 90 patients with severe combined immunodeficiency. Blood. 2009;113:4114–24.CrossRefPubMed
42.
Schuetz C, et al. SCID patients with ARTEMIS vs RAG deficiencies following HCT: increased risk of late toxicity in ARTEMIS-deficient SCID. Blood. 2014;123:281–9.CrossRefPubMedCentralPubMed
43.
Kamani NR, et al. Malignancies after hematopoietic cell transplantation for primary immune deficiencies: a report from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant. 2011;17:1783–9.CrossRefPubMedCentralPubMed
44.
Eapen M, et al. Long-term survival and late deaths after hematopoietic cell transplantation for primary immunodeficiency diseases and inborn errors of metabolism. Biol Blood Marrow Transplant. 2012;18:1438–45.CrossRefPubMedCentralPubMed
45.
Shah AJ, Kohn DB. Neurocognitive function of patients with severe combined immunodeficiency. Immunol Allergy Clin North Am. 2010;30:143–51.CrossRefPubMed
46.
Titman P, et al. Cognitive and behavioral abnormalities in children after hematopoietic stem cell transplantation for severe congenital immunodeficiencies. Blood. 2008;112:3907–13.CrossRefPubMed
47.
Walter AW, et al. Survival and neurodevelopmental outcome of young children with medulloblastoma at St Jude Children’s Research Hospital. J Clin Oncol. 1999;17:3720–8.PubMed
48.
Mathisen SE, Glavin K, Lien L, Lagerlov P. Prevalence and risk factors for postpartum depressive symptoms in Argentina: a cross-sectional study. Int J Women’s Health. 2013;5:787.CrossRef
49.
Lin M, et al. Long-term neurocognitive function of pediatric patients with severe combined immune deficiency (SCID): pre- and post-hematopoietic stem cell transplant (HSCT). J Clin Immunol. 2009;29:231–7.CrossRefPubMed
50.
Czechowicz A, Kraft D, Weissman IL, Bhattacharya D. Efficient transplantation via antibody-based clearance of hematopoietic stem cell niches. Science. 2007;318:1296–9.CrossRefPubMedCentralPubMed
51.
Straathof KC, et al. Haemopoietic stem-cell transplantation with antibody-based minimal-intensity conditioning: a phase 1/2 study. Lancet. 2009;374:912–20.CrossRefPubMed
52.
Hassan A, et al. Outcome of hematopoietic stem cell transplantation for adenosine deaminase-deficient severe combined immunodeficiency. Blood. 2012;120:3615–24.CrossRefPubMed
53.
Honig M, et al. Patients with adenosine deaminase deficiency surviving after hematopoietic stem cell transplantation are at high risk of CNS complications. Blood. 2007;109:3595–602.CrossRefPubMed
54.
O’Marcaigh AS, et al. Bone marrow transplantation for T-B- severe combined immunodeficiency disease in Athabascan-speaking native Americans. Bone Marrow Transplant. 2001;27:703–9.CrossRefPubMed
55.
Bertrand Y, et al. Influence of severe combined immunodeficiency phenotype on the outcome of HLA non-identical, T-cell-depleted bone marrow transplantation: a retrospective European survey from the European group for bone marrow transplantation and the european society for immunodeficiency. J Pediatr. 1999;134:740–8.CrossRefPubMed
56.
Dalal I, et al. Matched unrelated bone marrow transplantation for combined immunodeficiency. Bone Marrow Transplant. 2000;25:613–21.CrossRefPubMed
57.
Knutsen AP, Wall DA. Umbilical cord blood transplantation in severe T-cell immunodeficiency disorders: two-year experience. J Clin Immunol. 2000;20:466–76.CrossRefPubMed
58.
Bhattacharya A, et al. Single centre experience of umbilical cord stem cell transplantation for primary immunodeficiency. Bone Marrow Transplant. 2005;36:295–9.CrossRefPubMed
Metadata
Title
Hematopoietic Stem Cell Transplantation for Severe Combined Immunodeficiency
Authors
Justin T. Wahlstrom
Christopher C. Dvorak
Morton J. Cowan
Publication date
01-03-2015
Publisher
Springer US
Published in
Current Pediatrics Reports / Issue 1/2015
Electronic ISSN: 2167-4841
DOI
https://doi.org/10.1007/s40124-014-0071-7

Other articles of this Issue 1/2015

Current Pediatrics Reports 1/2015 Go to the issue

Immunology (HB Gaspar, Section Editor)

The Genetic and Molecular Basis of Severe Combined Immunodeficiency

Immunology (HB Gaspar, Section Editor)

Newborn Screening for Severe Combined Immunodeficiency

Renal (R Parekh, Section Editor)

Nephrotic Syndrome: State of the Art

Renal (R Parekh, Section Editor)

Rituximab Treatment for Nephrotic Syndrome in Children

Renal (R Parekh, Section Editor)

Acute Kidney Injury (AKI): Current Thoughts and Controversies in Pediatrics

Renal (R Parekh, Section Editor)

Genes in FSGS: Diagnostic and Management Strategies in Children